Human plasma fibrinogen measurement derived from activated partial thrornboplastin time clot formation

Blood Coagulation and Fibrinolysis

Volumn 13, Issue 1, 2002, Pages 61-68

  Sobas, F ^a   Hanss, M ^b   Ffrench, P ^b   Trzeciak, M C ^a   Dechavanne, M ^a   Negrier C ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b LOUIS PRADEL HOSPITAL   (France)

Author keywords

Activated partial thromboplastin time; Fibrinogen; Prothrombin time

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; HEPARIN;

ADULT; ARTICLE; ASSAY; BLOOD CLOTTING; BLOOD CLOTTING FACTOR DEFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; ENZYME IMMUNOASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL;

ADULT; AGED; ANTICOAGULANTS; BLOOD COAGULATION TESTS; COAGULATION PROTEIN DISORDERS; FEMALE; FIBRINOGEN; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER DISEASES; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS;

EID: 0036240071     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200201000-00010     Document Type: Article

References (38)

1. Genetic and cultural inheritance of plasma fibrinogen concentration
2. Fibrinogen as a risk for stroke and myocardial infarction
3. Fibrinogen and risk of cardiovascular disease. The Framingham study
4. Coagulation studies as a pronostic index in acute liver failure
5. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European cooperative study group for recombinant tissue-type plasminogen activator
6. Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): A study of 118 cases
7. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia
8. A monoclonal antibody-based quantitative enzyme immunoassay for the determination of plasma fibrinogen concentrations
9. Studies in the determination of fibrinogen in human blood plasma
10. Collaborative study of a proposed international standard for plasma fibrinogen measurement
11. Gerinnunsphysiologische schnellmethode zur bestimmung des fibrinogens
12. Comparison of the four fibrinogen assays during thrombolytic therapy
13. Studies on the functionality of fibrinogen during rt-PA therapy: Results of three different methods of fibrinogen determination
14. Evaluation of a fully automated centrifugal analyzer for performance of hemostasis tests
15. Measurement of plasma fibrinogen concentration by the prothrombin-time-derived method: Applicability and limitations
16. Prothrombin time derived fibrinogen determination on Sysmex CA-6000 TM
17. Relationship between fibrinogen concentrations and optical properties
18. Properties of optical data from activated partial thromboplastin time and prothrombin time assays
19. Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulometers
20. Comparison of a new automated kinetically determined fibrinogen assay with the 3 most used fibrinogen assays (functional, derived and nephelometric) in Austrian laboratories in several clinical populations and healthy controls
21. Inaccuracy of the derived fibrinogen measurement
22. Protocole VALTEC de la Société Française de Biologie Clinique
23. Thrombin generation in plasma: Its assesment via the endogenous thrombin potential
24. The international and 'NIH' units for thrombin - How do they compare?
25. Physiological studies on fibrin network structure
26. Studies on the ultrastructure of fibrin lacking fibrinopeptide B (β-fibrin)
27. Interaction of protamine sulfate with thrombin
28. Cold-induced contact surface activation of the prothrombin time in whole blood
29. Fibrinogen assays: A collaborative study of six different methods
30. Human fibrinogen-structural variants and functional sites
31. Glycosylation of human fibrinogen and fibrin in vitro, its consequences on the properties of fibrinogen(ogen)
32. Quantitative abnormality of an Aα chain molecular weight form in the fibrinogen of cirrhotic patients
33. Study of the formation of fibrin clot in cirrhotic patients. An approach to study of acquired dysfibrinogenaemia
34. Studies on fibrin network structure: The effect of some plasma proteins
35. Structure and functions of fibrinogen: Insights from dysfibrinogens
36. Quantitation of the three normally occuring plasma fibrinogens in health and during so called 'acute phase' by SDS electrophoresis of fibrin obtained from EDTA-plasma
37. Discrepancy between fibrinogen concentrations determined by clotting rate and clottability assays during the acute phase reaction
38. Elevated high molecular weight fibrinogen in plasma is predictive of coronary ischemic events after acute myocardial infarction